Arvinas Inc. (NASDAQ:ARVN) is one of the best low priced pharma stocks to buy now. Earlier on June 13, Arvinas presented encouraging preclinical data for its investigational PROteolysis TArgeting ...

This stock is one of several featured in our latest research. For more small-cap opportunities with asymmetric return ...

– John Houston, Ph.D., Chairperson, CEO and President at Arvinas, Announces Plans to Retire as CEO Upon Appointment of Successor – – Dr. Houston to Remain Chairperson of Arvinas Board of ...

Arvinas PROTAC protein degraders have some potential, with vepdegestrant as its late-stage, most promising asset, partnered with Pfizer. Read more on ARVN here.

NEW HAVEN, Conn., July 09, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, ...

Arvinas may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on such forward-looking statements.

Celcuity shares jump as gedatolisib shows strong efficacy in HR+/HER2- breast cancer Phase 3 trial, with FDA filing expected ...

– John Houston, Ph.D., Chairperson, CEO and President at Arvinas, Announces Plans to Retire as CEO Upon Appointment of Successor – – Dr. Houston to Remain Chairperson of Arvinas Board of Directors – – ...

NEW HAVEN, Conn. - Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company with a market capitalization of $585 million, announced Wednesday that John Houston, Ph.D., will retire from ...

Arvinas may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on such forward-looking statements.

Arvinas' top executive, John Houston, plans to retire after roughly eight years at the helm of the clinical-stage biotechnology company. Arvinas on Wednesday said Houston, who has been president ...

SmallCap stocks can often be overlooked by institutional investors, yet they offer outsized return potential for those ...